NEW YORK (GenomeWeb) – Diagnostics company InterVenn BioSciences said today it has raised $9.4 million in a funding round led by Genoa Ventures.

The Redwood City, California-based firm will use the funds to develop its lead product, a mass spectrometry-based blood test for ovarian cancer. The company said it is currently doing analytical and clinical validation for the test, which it ultimately plans to offer as a laboratory-developed test.